KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,

Slides:

Advertisements

Similar presentations

Advertisements

Gene Mutations.

13-3 Mutations Can be good, bad or nothing!!. What is a mutation? The word is Latin for “to change”. There are 2 types: – 1) Single gene changes – 2)

Microbial Genetics - Mutation l Mutation - Introduction –A mutation is a change in the DNA sequence that results in a change in the product protein –Mutations.

Types of Mutations Graphic Organizer

Point Mutations Silent Missense Nonsense Frameshift.

What exactly is a mutated gene? Nope, that’s not it.

 During replication (in DNA), an error may be made that causes changes in the mRNA and proteins made from that part of the DNA  These errors or changes.

Unit 6 Notes: Mutations. DNA Mutations Mutations: Any change in the sequence of nitrogenous bases of DNA. Causes: – Mutagens = factors that change chemical.

Mutation. What you need to know How alteration of chromosome number or structurally altered chromosomes can cause genetic disorders How point mutations.

DNA Mutations. Base Substitution: A substitution is a mutation that exchanges one base for another (switch A with a G) 1. changes a codon to one that.

Variation among organisms

Gene Mutations.

CYB561 mutations. CYB561 mutations. The upper part shows the structure of the CYB561 gene, with the positions of the identified mutations indicated. Gray.

Mutations Chapter 12-4.

Types of Mutations.

DNA and mutations SC.912.L.16.4.

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

Types of point mutations

WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1. Type and distribution within KCNQ2 protein of variants in self-limiting epilepsy vs epileptic encephalopathy Type and distribution within KCNQ2.

Genomic alterations in breast cancer cell line MDA-MB-231.

Mutational burden of somatic, protein-altering mutations per subject from WES for patients with advanced colon cancer who participated in PD-1 blockade.

Copy-number alterations in an archival breast cancer sample.

Mutations Any change in an organism’s DNA. Mutations in somatic cells only impact individual; mutations in gametes may impact offspring. 2 Types: A. Gene.

Nic’s genome contains 16,124 variants,

Topic #3: Types of Mutations

De Novo Mutations in the Sodium-Channel Gene SCN1A Cause Severe Myoclonic Epilepsy of Infancy Lieve Claes, Jurgen Del-Favero, Berten Ceulemans, Lieven.

Mutation: Some Definitions

Mutation Notes.

Figure 1 Pedigree and genetic findings

Sequences of two isoforms of Arhgap39/Porf-2 protein in mouse.

(A) yellow cDNA comparison among wild-type and ch mutants

Structure of PrfA (A) and its target DNA sequences in PrfA-regulated promoters (B). Structure of PrfA (A) and its target DNA sequences in PrfA-regulated.

Multiple sequence alignment of Twisted gastrulation (TSG) proteins.

BRCA1 promoter methylation detected in the peripheral blood and corresponding tumor. BRCA1 promoter methylation detected in the peripheral blood and corresponding.

In vitro interaction domain mapping of pVHL and AUF1.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

Frequent alterations identified and potential actionability.

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

Overview of TIMER modules on the website.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

ADNs are largely distinct from CDNs

Somatic mutational rates and survival analysis of IBD-CRC.

Positions of the EGFR exon 20 insertions identified over a 3-year period and comparison with the spectrum of EGFR exon 19 and HER2 insertion mutations.

Location of common clinically relevant mutations in EGFR

Comparison of the frequency of nucleotide variation in the mtDNA D-loop region between stomach and other tumor cell lines. Comparison of the frequency.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Neurodegenerative Tauopathies

Representative photograph of somatic mutations detected by PCR-SSCP.

Structures of wild-type and mutated recombinant CDX2.

Location of the ER mutations and frequencies per cohort.

Histology (H&E; original magnification, ×100 for B-2P/C-12P/C-64P and ×40 for C-10P; top) of small-sized lung adenocarcinomas and immunohistochemical staining.

Global mutational landscape of the 170 lung adenocarcinoma patients (discovery cohort). Global mutational landscape of the 170 lung adenocarcinoma patients.

Molecular definitions of lung adenocarcinoma subtypes.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

Genetic analysis suggests the presence of four clinically relevant groups of histologically defined anaplastic oligodendrogliomas. Genetic analysis suggests.

Predicted pathogenic BRCA1 amino acid substitutions are confined to the evolutionarily conserved N- and C-terminal domains. Predicted pathogenic BRCA1.

Enrichment of two rare SNPs among ABC DLBCL tumors.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

Driver pathways and key genes in OSCC

Presentation transcript:

KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids, mutations (insertion or deletion) and the corresponding amino acid substitution. KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids, mutations (insertion or deletion) and the corresponding amino acid substitution. Italicized and underscored amino acids, missense mutations and the corresponding amino acid substitution. Shaded box, amino acids 556 to 560 which are altered in the majority of tumors examined. B, high frequency of missense mutations in KIT exon 11 encoding amino acids 556 to 560. Summary of amino acid substitutions reported by us (in this report) and others (36, 39, 40). Chi Tarn et al. Clin Cancer Res 2005;11:3668-3677 ©2005 by American Association for Cancer Research